

Efficacy of Intracolonic Administration of Low-Molecular-Weight Heparin CB-01-05, Compared to Other Low-Molecular-Weight Heparins and Unfractionated Heparin, in Experimentally Induced Colitis in Rat

**Giuseppe Celasco · Luigi Moro · Roberta Bozzella · Katia Mangano ·
Cinzia Quattrocchi · Caterina Aiello · Marco Donia · Paolo Fagone ·
Roberto Di Marco**

Published online: 4 June 2008
© Springer Science+Business Media, LLC 2008

Erratum to: Dig Dis Sci
DOI 10.1007/s10620-008-0299-6

The following error was published in Table 2 of this article.

LMWH-A, LMWH-C, and UFH are not properly aligned. This makes it impossible to link the drugs to the correct doses and to the effects, and so the information is greatly misleading. The correct Table 2 appears below.

The online version of the original article can be found under
doi:[10.1007/s10620-008-0299-6](https://doi.org/10.1007/s10620-008-0299-6).

G. Celasco (✉) · L. Moro · R. Bozzella
Cosmo Research and Development Srl, Via C. Colombo 1,
20020 Lainate, MI, Italy
e-mail: giuseppe.celasco@cosmopharmaceuticals.com

K. Mangano · C. Quattrocchi · C. Aiello · M. Donia · P. Fagone
Dipartimento di Scienze Biomediche, Università di Catania,
Catania, Italy

R. D. Marco
Dipartimento di Scienze per la Salute, Università del Molise,
Campobasso, Italy

R. D. Marco
Istituto Neurologico del Mediterraneo, Neuromed, Pozzilli, IS,
Italy

Table 2 Effect of CB-01-05, other LMWHs, and UFH in DNB-induced experimental colitis in rat (mean values \pm SD)

Assay no.	Intracolonic treatment	Daily dose (mg)	Av. body weight (g)		Distal colon weight (g/10 cm)	Mucosal damaged area (MDA) (mm ²)	Histological score (HS)
			Initial	Final			
I	Control	–	239 \pm 15.1	223 \pm 17.2	1.93 \pm 0.3	689.1 \pm 138.2	9.1 \pm 2.5
	CB-01-05	0.005	239 \pm 13.0	223 \pm 16.1	2.19 \pm 0.6	712.1 \pm 233.9	9.1 \pm 3.0
		0.016	246 \pm 3.3	228 \pm 8.9	1.99 \pm 0.2	721.3 \pm 67.7	9.0 \pm 1.2
		0.06	246 \pm 4.2	225 \pm 15.7	2.10 \pm 0.5	653.1 \pm 202.0	6.9 \pm 1.8
		0.2	245 \pm 5.3	239 \pm 8.8	1.59 \pm 0.4	516.0 \pm 184.9	5.3 \pm 2.4*
		0.6	236 \pm 17.1	224 \pm 16.9	1.50 \pm 0.3 *	393.6 \pm 166.9*	4.0 \pm 1.7*
II	Control	–	240 \pm 11.2	225 \pm 9.9	1.88 \pm 0.4	711.9 \pm 137.5	8.4 \pm 2.3
	CB-01-05	0.3	244 \pm 4.9	226 \pm 8.3	1.52 \pm 0.5	557.3 \pm 142.6*	5.5 \pm 3.2*
		0.6	242 \pm 11.2	231 \pm 12.2	1.25 \pm 0.2*	382.2 \pm 162.1*	4.2 \pm 1.41*
		0.9	243 \pm 10.6	233 \pm 14.7	1.22 \pm 0.4*	369.8 \pm 185.3*	3.5 \pm 2.1*
	LMWH-A	0.6	238 \pm 8.8	225 \pm 13.5	1.74 \pm 0.5	586.0 \pm 183.4	6.0 \pm 2.7
	LMWH-C	0.6	239 \pm 9.8	224 \pm 6.4	1.85 \pm 0.2	524.4 \pm 292.5	8.3 \pm 1.9
III	Control	–	242 \pm 7.1	218 \pm 9.9	1.90 \pm 0.20	486.5 \pm 106.2	n.a.
	LMWH-B	0.3	244 \pm 9.7	223 \pm 10.2	1.80 \pm 0.30	391.8 \pm 238.7	n.a.
		0.6	250 \pm 6.4	224 \pm 8.8	1.80 \pm 0.20	420.2 \pm 212.3	n.a.
	UFH	0.6	253 \pm 10.1	238 \pm 11.6	1.70 \pm 0.30	312.5 \pm 209.4	n.a.

* $P < 0.01$ versus the relevant control group. n.a. = not assessed; LMWH = low-molecular-weight heparin; UFH = unfractionated heparin